文献速递免疫规划慢病防控与筛查

透析患者mRNA与蛋白亚单位SARS-CoV-2疫苗免疫原性比较:多中心研究

Comparison of immunogenicity of mRNA and protein subunit SARS-CoV-2 vaccines in dialysis patients: a multicenter study.
PubMed 文献 · Vaccine · 2026-06-20

该观察性研究纳入227名参与者(202名维持性血液透析患者和25名非透析个体),在2024年疫苗接种季接种BNT162b2(mRNA疫苗)或NVX-CoV2373(蛋白亚单位疫苗)。主要结局为第4周抗SARS-CoV-2刺突抗体水平,第24周评估长期持续性。结果显示在透析患者和非透析个体中,BNT162b2诱导的抗体水平均显著高于NVX-CoV2373;既往不良事件未阻碍选择BNT162b2(OR 8.08, 95% CI 0.98-66.5)。

要点

  • 在透析患者中,BNT162b2第4周诱导的抗刺突抗体水平显著高于NVX-CoV2373。
  • 非透析个体中BNT162b2同样诱导更高抗体水平,但样本量有限。
  • 两种疫苗组抗体水平至第24周均下降,但组间差异持续存在。

核心结论

  • 在维持性血液透析患者中,BNT162b2接种后预定时间点的抗刺突抗体水平高于NVX-CoV2373。
  • 非透析个体中BNT162b2也诱导更高抗体水平,但样本量有限。
  • 既往不良事件未阻碍选择BNT162b2,但该关联可能反映参与者认知或其他未测量因素。

研究设计与样本

  • 观察性研究,纳入227名参与者(202名维持性血液透析患者和25名非透析个体)。
  • 2024年疫苗接种季接种BNT162b2(mRNA疫苗)或NVX-CoV2373(蛋白亚单位疫苗)。
  • 在第0、4、24周评估抗SARS-CoV-2刺突抗体水平,第4周为主要结局,第24周为次要时间点评估长期持续性。
  • 评估既往不良事件与疫苗选择之间的关联。

主要发现

  • 第4周时,在血液透析患者中BNT162b2诱导的抗体水平显著高于NVX-CoV2373。
  • 在非透析个体中,BNT162b2同样诱导显著更高的抗体水平。
  • 两种疫苗组抗体水平至第24周均下降,但组间差异持续至第24周。
  • 既往不良事件未阻碍选择BNT162b2(OR 8.08, 95% CI 0.98-66.5)。
  • 非透析亚组样本量有限,但仍显示BNT162b2组抗体水平更高。

关键数值与推荐

  • 主要结局为第4周抗SARS-CoV-2刺突抗体水平。
  • BNT162b2组第4周抗体水平显著高于NVX-CoV2373组(透析患者和非透析个体均如此)。
  • 既往不良事件与选择BNT162b2的OR为8.08(95% CI 0.98-66.5)。

临床怎么用

  • 对于维持性血液透析患者,选择BNT162b2可能获得更高的短期抗刺突抗体水平。
  • 需注意抗体水平随时间下降,即使第24周组间差异仍存在。
  • 疫苗选择时应考虑抗体反应差异,但需结合临床结局综合判断。

局限性

  • 未评估临床结局(如感染、重症或死亡)。
  • 未进行正式的抗体衰减建模。
  • 非透析亚组样本量有限。
  • 既往不良事件与疫苗选择的关联可能受参与者认知或其他未测量因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients on maintenance hemodialysis (HD) have impaired immune function and are at high risk of severe COVID-19; however, comparative data on immunogenicity and vaccine choice behavior between mRNA and protein subunit SARS-CoV-2 vaccines remain limited. In this observational study, 227 participants (202 patients on HD and 25 non-dialysis individuals) received either an mRNA vaccine (BNT162b2) or a protein subunit vaccine (NVX-CoV2373) in 2024 vaccination season. Anti-SARS-CoV-2 spike antibody levels were assessed at weeks 0, 4, and 24, with week 4 defined as the primary outcome and week 24 as a secondary time point for longer-term persistence; the association between previous adverse events and vaccine choice was evaluated. At week 4, BNT162b2 induced significantly higher antibody levels than NVX-CoV2373 in patients on HD. BNT162b2 also induced significantly higher antibody levels than NVX-CoV2373 in non-dialysis individuals. Antibody levels declined by week 24 in both vaccine groups, although differences in antibody levels were observed up to week 24. Previous adverse events did not deter selection of BNT162b2 (OR 8.08, 95% CI 0.98-66.5), although this association may reflect participant perceptions or other unmeasured factors. Non-dialysis subgroup with limited number of patients also showed higher antibody levels in the BNT162b2 group. These findings suggest that BNT162b2 is associated with higher anti-spike antibody levels at predefined post-vaccination time points in patients on HD. However, these findings should be interpreted cautiously because clinical outcomes and formal antibody decay modeling were not evaluated.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Morio R, Takazono T, Morimoto S, et al. Comparison of immunogenicity of mRNA and protein subunit SARS-CoV-2 vaccines in dialysis patients: a multicenter study. Vaccine. 2026. PMID: 42322683. doi:10.1016/j.vaccine.2026.128861

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。